Abstract:Copper is an element required for cell proliferation and angiogenesis. Human prostate cancer xenografts with increased Cu-64 radioactivity were visualized previously by PET using (CuCl2)-Cu-64 as a radiotracer ((CuCl2)-Cu-64 PET). This study aimed to determine whether the increased tumor 64Cu radioactivity was due to increased cellular uptake of 64Cu mediated by human copper transporter 1 (hCtr1) or simply due to nonspecific binding of ionic 64CuCl2 to tumor tissue. In addition, the functional role of hCtr1 in proliferation of prostate cancer cells and tumor growth was also assessed. Methods: A lentiviral vector encoding short-hairpin RNA specific for hCtr1 (Lenti-hCtr1-shRNA) was constructed for RNA interference-mediated knockdown of hCtr1 expression in prostate cancer cells. The degree of hCtr1 knockdown was determined by Western blot, and the effect of hCtr1 knockdown on copper uptake and proliferation were examined in vitro by cellular 64Cu uptake and cell proliferation assays. The effects of hCtr1 knockdown on tumor uptake of 64Cu were determined by PET quantification and tissue radioactivity assay. The effects of hCtr1 knockdown on tumor growth were assessed by PET/CT and tumor size measurement with a caliper. Results: RNA interference-mediated knockdown of hCtr1 was associated with the reduced cellular uptake of 64Cu and the suppression of prostate cancer cell proliferation in vitro. At 24 h after intravenous injection of the tracer 64CuCl2, the 64Cu uptake by the tumors with knockdown of hCtr1 (4.02 +/- 0.31 percentage injected dose per gram [% ID/g] in Lenti-hCtr1-shRNA-PC-3 and 2.30 +/- 0.59 % ID/g in Lenti- hCtr1- shRNA- DU- 145) was significantly lower than the 64Cu uptake by the control tumors without knockdown of hCtr1 (7.21 +/- 1.48% ID/g in Lenti-SCR-shRNA-PC-3 and 5.57 +/- 1.20% ID/g in Lenti-SCR-shRNA-DU-145, P, 0.001) by PET quantification. Moreover, the volumes of prostate cancer xenograft tumors with knockdown of hCtr1 (179 +/- 111 mm(3) for Lenti-hCtr1-shRNAPC- 3 or 39 +/- 22 mm(3) for Lenti-hCtr1-shRNA-DU-145) were significantly smaller than those without knockdown of hCtr1 (536 +/- 191 mm(3) for Lenti-SCR-shRNA-PC-3 or 208 +/- 104 mm(3) for Lenti-SCR-shRNA-DU-145, P, 0.01). Conclusion: Overall, data indicated that hCtr1 is a promising theranostic target, which can be further developed for metabolic imaging of prostate cancer using (CuCl2)-Cu-64 PET/CT and personalized cancer therapy targeting copper metabolism.

Development and Use of Human Recombinant 64Cu-rHCF as a Kidney Glomerulus-Targeted Contrast Agent for Positron Emission Tomography

Mouse Extrahepatic Hepatoma Detected on MicroPET Using Copper (II)-64 Chloride Uptake Mediated by Endogenous Mouse Copper Transporter 1

Fine-tuned H-Ferritin Nanocage with Multiple Gold Clusters As Near-Infrared Kidney Specific Targeting Nanoprobe.

Preparation of [ 64 Cu]Cu–NOTA complex as a potential renal PET imaging agent using 64 Cu produced via the direct activation route

Targeted design of a recombinant tracer for SPECT renal imaging

High-Performance Renal Imaging With A Radiolabeled Non-Excretable Chimeric Fusion Protein

Pet Imaging of C-Met in Cancer with Cu-64-Labeled Hepatocyte Growth Factor

A Targeted Nanoglobular Contrast Agent from Host-Guest Self-Assembly for MR Cancer Molecular Imaging.

Positron Emission Tomography Imaging of Tumor Angiogenesis with a (61/64)Cu-Labeled F(ab')(2) Antibody Fragment.

Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.

Initial Preclinical Evaluation of 18F-Fluorodeoxysorbitol PET as a Novel Functional Renal Imaging Agent

Reduced 64cu Uptake and Tumor Growth Inhibition by Knockdown of Human Copper Transporter 1 in Xenograft Mouse Model of Prostate Cancer.

Synthesis and Evaluation of [ 64 Cu]Cu-NOTA-HFn for PET Imaging of Transferrin Receptor 1 Expression in Nasopharyngeal Carcinoma

First-in-human Evaluation of Safety and Dosimetry of [64Cu]FBP8: A fibrin-binding PET Probe

Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with 61Cu-Labeled Lysine-Tagged VEGF121

The use of ferumoxytol for high-resolution vascular imaging and troubleshooting for abdominal allografts

MRI contrast demonstration of antigen-specific targeting with an iron-based ferritin construct

Synthesis and Biological Evaluation of a Radiolabeled PET (Positron Emission Tomography) Probe for Visualization of In Vivo α-Fucosidase Expression

PET imaging of CD105/endoglin expression with a 61/64 Cu-labeled Fab antibody fragment

Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging

PET of CD105 Expression with a 61/64Cu-Labeled Fab Antibody Fragment